Evidence map›Paper›PMID 30355653›Full record

ArticleBioscience reports2018

Down-regulation of siglec-2 (CD22) predicts worse overall survival from HBV-related early-stage hepatocellular carcinoma: a preliminary analysis from Gene Expression Omnibus.

Xiaojing Ren, Yuanyuan Ji, Xuhua Jiang, Xun Qi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioscience reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 83% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Xiaojing RenDepartment of Liver Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
Yuanyuan JiDepartment of Liver Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
Xuhua JiangDepartment of Liver Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
Xun QiDepartment of Liver Disease, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China qixun@shphc.org.cn.
Shanghai Public Health Clinical Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sialic-acid-binding immunoglobulin-like lectin (siglec) regulates cell death, anti-proliferative effects and mediates a variety of cellular activities. Little was known about the relationship between siglecs and hepatocellular carcinoma (HCC) prognosis. Siglec gene expression between tumor and non-tumor tissues were compared and correlated with overall survival (OS) from HCC patients in GSE14520 microarray expression profile. Siglec-1 to siglec-9 were all down-regulated in tumor tissues compared with those in non-tumor tissues in HCC patients (all

Indexed as

PrognosisAdultalpha-FetoproteinsAntigens, CDCarcinoma, HepatocellularDisease-Free SurvivalFemaleGene Expression Regulation, NeoplasticHepatitis B virusHumansKaplan-Meier EstimateLiver NeoplasmsMaleMiddle AgedSialic Acid Binding Ig-like Lectin 1Sialic Acid Binding Ig-like Lectin 2alpha-FetoproteinsAntigens, CDCD22 protein, humanSialic Acid Binding Ig-like Lectin 1Sialic Acid Binding Ig-like Lectin 2Sialic Acid Binding Immunoglobulin-like LectinsSIGLEC1 protein, humanSIGLEC9 protein, humanalpha-fetoproteinhepatocellular carcinomaoverall survivalprognosissiglec-2

Identifiers

PMID30355653
PMCPMC6259014
OpenAlexW2898283483

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.